Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 204

1.

Novel evidence-based systemic lupus erythematosus responder index.

Furie RA, Petri MA, Wallace DJ, Ginzler EM, Merrill JT, Stohl W, Chatham WW, Strand V, Weinstein A, Chevrier MR, Zhong ZJ, Freimuth WW.

Arthritis Rheum. 2009 Sep 15;61(9):1143-51. doi: 10.1002/art.24698.

PMID:
19714615
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.

Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, Petri MA, Ginzler EM, Chatham WW, McCune WJ, Fernandez V, Chevrier MR, Zhong ZJ, Freimuth WW.

Arthritis Rheum. 2009 Sep 15;61(9):1168-78. doi: 10.1002/art.24699.

PMID:
19714604
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.

Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, Sanchez-Guerrero J, Schwarting A, Merrill JT, Chatham WW, Stohl W, Ginzler EM, Hough DR, Zhong ZJ, Freimuth W, van Vollenhoven RF; BLISS-76 Study Group.

Arthritis Rheum. 2011 Dec;63(12):3918-30. doi: 10.1002/art.30613.

PMID:
22127708
[PubMed - indexed for MEDLINE]
Free Article
4.

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.

Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, Li EK, Thomas M, Kim HY, León MG, Tanasescu C, Nasonov E, Lan JL, Pineda L, Zhong ZJ, Freimuth W, Petri MA; BLISS-52 Study Group.

Lancet. 2011 Feb 26;377(9767):721-31. doi: 10.1016/S0140-6736(10)61354-2. Epub 2011 Feb 4.

PMID:
21296403
[PubMed - indexed for MEDLINE]
5.

Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.

Petri MA, van Vollenhoven RF, Buyon J, Levy RA, Navarra SV, Cervera R, Zhong ZJ, Freimuth WW; BLISS-52 and BLISS-76 Study Groups.

Arthritis Rheum. 2013 Aug;65(8):2143-53. doi: 10.1002/art.37995.

PMID:
23754628
[PubMed - indexed for MEDLINE]
6.

Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials.

Manzi S, Sánchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, Ginzler EM, D'Cruz DP, Doria A, Cooper S, Zhong ZJ, Hough D, Freimuth W, Petri MA; BLISS-52 and BLISS-76 Study Groups.

Ann Rheum Dis. 2012 Nov;71(11):1833-8. doi: 10.1136/annrheumdis-2011-200831. Epub 2012 May 1.

PMID:
22550315
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response.

van Vollenhoven RF, Petri MA, Cervera R, Roth DA, Ji BN, Kleoudis CS, Zhong ZJ, Freimuth W.

Ann Rheum Dis. 2012 Aug;71(8):1343-9. doi: 10.1136/annrheumdis-2011-200937. Epub 2012 Feb 15.

PMID:
22337213
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Belimumab: review of use in systemic lupus erythematosus.

Boyce EG, Fusco BE.

Clin Ther. 2012 May;34(5):1006-22. doi: 10.1016/j.clinthera.2012.02.028. Epub 2012 Mar 30. Review.

PMID:
22464040
[PubMed - indexed for MEDLINE]
9.

Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50 enhances the ability of SLE Responder Index to identify responders in clinical trials.

Touma Z, Gladman DD, Ibañez D, Taghavi-Zadeh S, Urowitz MB.

J Rheumatol. 2011 Nov;38(11):2395-9. doi: 10.3899/jrheum.110550. Epub 2011 Sep 1.

PMID:
21885488
[PubMed - indexed for MEDLINE]
10.

Belimumab: in systemic lupus erythematosus.

Burness CB, McCormack PL.

Drugs. 2011 Dec 24;71(18):2435-44. doi: 10.2165/11208440-000000000-00000. Review.

PMID:
22141386
[PubMed - indexed for MEDLINE]
11.

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial.

Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D, Brunetta PG.

Arthritis Rheum. 2010 Jan;62(1):222-33. doi: 10.1002/art.27233.

PMID:
20039413
[PubMed - indexed for MEDLINE]
Free Article
12.

Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus.

Stohl W, Hiepe F, Latinis KM, Thomas M, Scheinberg MA, Clarke A, Aranow C, Wellborne FR, Abud-Mendoza C, Hough DR, Pineda L, Migone TS, Zhong ZJ, Freimuth WW, Chatham WW; BLISS-52 Study Group; BLISS-76 Study Group.

Arthritis Rheum. 2012 Jul;64(7):2328-37. doi: 10.1002/art.34400.

PMID:
22275291
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus.

Ho A, Magder LS, Barr SG, Petri M.

Arthritis Rheum. 2001 Oct;44(10):2342-9.

PMID:
11665975
[PubMed - indexed for MEDLINE]
14.

A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients.

Lu TY, Ng KP, Cambridge G, Leandro MJ, Edwards JC, Ehrenstein M, Isenberg DA.

Arthritis Rheum. 2009 Apr 15;61(4):482-7. doi: 10.1002/art.24341.

PMID:
19333973
[PubMed - indexed for MEDLINE]
Free Article
15.

Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus.

Dörner T, Kaufmann J, Wegener WA, Teoh N, Goldenberg DM, Burmester GR.

Arthritis Res Ther. 2006;8(3):R74. Epub 2006 Apr 21. Erratum in: Arthritis Res Ther. 2008;10(5):406.

PMID:
16630358
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Efficacy and safety of biologic therapies for systemic lupus erythematosus treatment: systematic review and meta-analysis.

Borba HH, Wiens A, de Souza TT, Correr CJ, Pontarolo R.

BioDrugs. 2014 Apr;28(2):211-28. doi: 10.1007/s40259-013-0074-x.

PMID:
24190520
[PubMed - in process]
17.

B-cell targeted therapies in systemic lupus erythematosus: successes and challenges.

Harvey PR, Gordon C.

BioDrugs. 2013 Apr;27(2):85-95. doi: 10.1007/s40259-013-0015-8.

PMID:
23456653
[PubMed - indexed for MEDLINE]
18.

Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial.

Zimmer R, Scherbarth HR, Rillo OL, Gomez-Reino JJ, Muller S.

Ann Rheum Dis. 2013 Nov;72(11):1830-5. doi: 10.1136/annrheumdis-2012-202460. Epub 2012 Nov 21.

PMID:
23172751
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Correlation of ESR, C3, C4, anti-DNA and lupus activity based on British Isles Lupus Assessment Group Index in patients of rheumatology clinic.

Nasiri S, Karimifar M, Bonakdar ZS, Salesi M.

Rheumatol Int. 2010 Nov;30(12):1605-9. doi: 10.1007/s00296-009-1201-3. Epub 2009 Oct 7.

PMID:
19809816
[PubMed - indexed for MEDLINE]
20.

Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus.

Szepietowski JC, Nilganuwong S, Wozniacka A, Kuhn A, Nyberg F, van Vollenhoven RF, Bengtsson AA, Reich A, de Vries DE, van Hartingsveldt B, Robinson DW Jr, Gordon R, Hsu B.

Arthritis Rheum. 2013 Oct;65(10):2661-71. doi: 10.1002/art.38091.

PMID:
23896980
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk